腎細胞癌における遺伝子組換えインターフェロンγの末梢血リンパ球サブセットにおよぼす影響と投与方法の検討について

Abstract

1)術後IFN-γの周期的投与(B法)を1年間再発転移予防目的で行い, ADCC活性は投与2週後に上昇し, NK活性は6ヵ月後に上昇する傾向にあり, 1年後まで持続した。2)有意ではないが, 持続的投与法(A法)およびB投与法にかかわらず, 両活性は1年後で上昇する傾向にあった。3) CD4/8は投与につれ減少する傾向がみられ, 1年後で両投与群ともに, 1.6であった。4)臨床上有効であった2例は, 臨床上の効果と一致して活性値の上昇がみられた

Immunological effect of recombinant interferon gamma (IFN-gamma) was studied in 18 cases of renal cell carcinoma. Sixteen of them were administered IFN-gamma as post-operative adjuvant therapy. Two of them were administered IFN-gamma for metastatic renal cell carcinoma. All of them were followed for at least 1 year. We divided the patients into two groups. One group subcutaneously received IFN-gamma every other day for 16 days, then 4 weeks later every week for one year (group A), and the other group, received alternate subcutaneous IFN-gamma every other day for 16 days and every week for 4 weeks (group B). For immunological testing, peripheral blood lymphocytes were obtained before treatment on day 1, 2 weeks later, 6 months later and 12 months later. The cells were tested for natural killer activity (NK), antibody dependent cellular cytotoxicity (ADCC), positive lymphocytes of CD3, CD4, CD8 and CD11b. Both ADCC and NK activity were increased after therapy, especially in group B. CD3, CD4 and CD8 positive lymphocytes were increased by means of IFN-gamma. On the other hand, CD11b-positive lymphocytes could not be elicited in group B. Tumor regression was observed in 2 cases of metastatic renal cell carcinomas. When clinical responses were observed, both ADCC and NK were elicited as compared with the pretreatment values. Our findings indicated that ADCC and NK could be elicited in group B.